A 12-month review of peritoneal dialysis-related peritonitis in Western Australia: Is empiric vancomycin still indicated for some patients?

Peritoneal Dialysis International

Volumn 23, Issue 5, 2003, Pages 465-468

  Kan, George W ^a,b   Thomas, Mark A B ^a   Heath, Christopher H ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Aborigine; Antimicrobial resistance; Coagulase negative staphylococci; Fungal; Gentamicin; Peritonitis; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFAZOLIN; CEFTAZIDIME; COAGULASE; GENTAMICIN; METICILLIN; VANCOMYCIN;

ABORIGINE; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AUSTRALIA; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; FEASIBILITY STUDY; GRAM NEGATIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; MYCOSIS; NONHUMAN; PATIENT REFERRAL; PERITONEAL DIALYSIS; PERITONITIS; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE; RETROSPECTIVE STUDY; REVIEW; STATISTICAL ANALYSIS; TREATMENT INDICATION; UNIVERSITY HOSPITAL;

EID: 0142150145     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080302300511     Document Type: Review

References (12)

1. Keane WT, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, et al. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update [Published erratum appears in Perit Dial Int 2000; 20:828-9]. Perit Dial Int 2000; 20:396-411.
2. Cass A, Cunningham J, Wang Z, Hoy W. Indigenous health. Regional variation in the incidence of end-stage renal disease in indigenous Australians. Med J Aust 2001; 175:24-7.
3. Maguire GP, Arthur AD, Boustead BJ, Dwyer B, Currie BJ. Emerging epidemic of community-acquired methicillin-resistant Staphylococcus aureus infection in the Northern Territory. Med J Aust 1996; 164:721-3.
4. Zelenitsky S, Barns L, Findlay I, Alfa M, Ariano R, Fine A, et al. Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. Am J Kidney Dis 2000; 36:1009-13.
5. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing, 11th Information Supplement. Wayne, PA: National Committee for Clinical Laboratory Standards; 2001(21): M100-21.
6. Gradelski E, Valera L, Aleksunes L, Bonner D, Fung-Tome J. Correlation between genotype and phenotypic characterization of staphylococci based on methicillin susceptibility and resistance. J Clin Microbiol 2001; 39:2961-3.
7. Murphy BF, Harris DCH, Disney A, Ibels L, Saltissi D, Rigby R, et al. Treatment of peritoneal dialysis related peritonitis - an Australian and New Zealand perspective. Aust N Z J Med 1999; 29:552-5.
8. Kent JR, Almond MK. A survey of CAPD peritonitis management and outcomes in North and South Thames NHS regions (U.K.): support for the ISPD guidelines. Perit Dial Int 2000; 20:301-5.
9. Vas SI, Bargman J, Oreopoulos DG. Treatment in PD patients of peritonitis caused by gram-positive organisms with single doses of antibiotics. Perit Dial Int 1997; 17:91-4.
10. Wong KM, Chan YH,, Cheung CY, Chak WL, Choi KS, Leung J, et al. Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. Am J Kidney Dis 2001; 38:127-31.
11. Goldberg L, Clemenger M, Azadian B, Brown E. Initial treatment of peritoneal dialysis peritonitis without vancomycin with a once-daily cefazolin-based regimen. Am J Kidney Dis 2001; 37:49-55.
12. Chan MK, Cheng IK, Ng WS. A randomized prospective trial of three different regimens of treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2001; 15:155-9.